(Q45399630)

English

Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles

scientific article published on 17 October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

0 references

human parainfluenza

1 reference

based on heuristic

inferred from title

author name string

Greer CE

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Zhou F

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Goodsell A

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Legg HS

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Tang Z

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

zur Megede J

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Uematsu Y

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Polo JM

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Vajdy M

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

17 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Scandinavian Journal of Immunology

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

645-653

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Cold adaptation of parainfluenza virus type 3: Induction of three phenotypic markers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized wit

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Virus-based vectors for human vaccine applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Sindbis virus: an efficient, broad host range vector for gene expression in animal cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Microparticles for intranasal immunization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

The role of antibody concentration and avidity in antiviral protection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.02019.X

21 January 2018

Identifiers

10.1111/J.1365-3083.2007.02019.X

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45399630&oldid=2130403573"